Nausea and vomiting with high-dose chemotherapy and stem cell rescue therapy: a review of antiemetic regimens.
Stem cell transplantation, using high-dose chemotherapy with or without TBI, is usually associated with significant nausea and vomiting. A variety of antiemetic regimens have been studied to control nausea and vomiting associated with the preparative therapy phase of SCT. We review the most significant studies and highlight the limitations of many of these studies. In addition, we review the few studies with the use of aprepitant as an antiemetic in combination with a 5HT(3) antagonist and a steroid. The American Society of Clinical Oncology guideline for antiemetic use for treatment regimens that are highly emetogenic is reviewed regarding recommendations for SCT preparative regimens. On the basis of this review of published data, we recommend the basic outline for an effective antiemetic investigational approach to the study and to the control of nausea and vomiting during the preparative phase of treatment for SCT.
Trigg
M E
ME
Department of Pediatrics, Thomas Jefferson University, Wilmington, DE, USA. michael_trigg@merck.com
Inverso
D M
DM
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009325:Nausea / Q000188:drug therapy* / Q000209:etiology; D009369:Neoplasms / Q000628:therapy; D017410:Practice Guidelines as Topic; D012702:Serotonin Antagonists / Q000627:therapeutic use; D012955:Societies, Medical; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014481:United States; D014839:Vomiting / Q000188:drug therapy* / Q000209:etiology
D000932:Antiemetics; D000970:Antineoplastic Agents; D012702:Serotonin Antagonists